Caroline Loewy
Director/Board Member bei EFFECTOR THERAPEUTICS, INC.
Vermögen: 23 087 $ am 31.03.2024
Profil
Caroline M.
Loewy was the founder and had founded Achieve Life Sciences, Inc. in 1991, where she held the title of Chief Financial & Business Officer from 2015 to 2017.
She is currently working as a Director at Kcnq2 Cure Alliance, Inc. since 2014, as a Founding Director at Global Genes since 2009, and as a Director at eFFECTOR Therapeutics, Inc. since 2023.
Ms. Loewy has previously worked as an Independent Director at Aptose Biosciences, Inc. from 2018 to 2022, as a Managing Director-Biotechnology Equity Research at Prudential Securities from 1996 to 2000, as an Independent Director at PhaseBio Pharmaceuticals, Inc. from 2018 to 2023, as an Independent Director at Zogenix, Inc. from 2020 to 2022, as an Independent Director at Locust Walk Acquisition Corp.
in 2021, as an Independent Director at Phoenix Biotech Acquisition Corp., as an Independent Director at CymaBay Therapeutics, Inc. from 2016 to 2024, as the Chief Financial Officer at Poniard Pharmaceuticals, Inc. from 2006 to 2008, as the Chief Financial Officer at Corcept Therapeutics, Inc. from 2008 to 2011, as a Research Analyst at Morgan Stanley & Co. LLC in 2004, and as the Chief Financial Officer at Tobira Therapeutics, Inc. from 2012 to 2014.
Ms. Loewy holds a graduate degree and an MBA from Carnegie Mellon University, and an undergraduate degree from the University of California, Berkeley (conferred in 1988).
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,04% | 14.02.2024 | 5 828 ( 0,04% ) | 17 892 $ | 31.03.2024 |
| 29.02.2024 | 361 ( 0,01% ) | 5 195 $ | 31.03.2024 | |
| 19.05.2023 | 3 750 ( 0,01% ) | - $ | 31.01.2024 |
Aktive Positionen von Caroline Loewy
| Unternehmen | Position | Beginn |
|---|---|---|
| EFFECTOR THERAPEUTICS, INC. | Director/Board Member | 11.09.2023 |
Global Genes
 Global Genes Miscellaneous Commercial ServicesCommercial Services Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin. | Director/Board Member | 01.06.2009 |
| Kcnq2 Cure Alliance, Inc. | Director/Board Member | 01.10.2014 |
Ehemalige bekannte Positionen von Caroline Loewy
| Unternehmen | Position | Ende |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Director/Board Member | 22.03.2024 |
| PHASEBIO PHARMACEUTICALS, INC. | Director/Board Member | 27.09.2023 |
| APTOSE BIOSCIENCES INC. | Director/Board Member | 31.05.2022 |
| ZOGENIX, INC. | Director/Board Member | 07.03.2022 |
| EFFECTOR THERAPEUTICS, INC. | Director/Board Member | 01.08.2021 |
Ausbildung von Caroline Loewy
| Carnegie Mellon University | Graduate Degree |
| University of California, Berkeley | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| PONIARD PHARMACEUTICALS, INC. | Health Technology |
| APTOSE BIOSCIENCES INC. | Health Technology |
| CORCEPT THERAPEUTICS INCORPORATED | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| ACHIEVE LIFE SCIENCES, INC. | Health Technology |
| EFFECTOR THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
| Prudential Securities | Finance |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Finance |
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
| Kcnq2 Cure Alliance, Inc. | |
Global Genes
Global Genes Miscellaneous Commercial ServicesCommercial Services Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin. | Commercial Services |
Locust Walk Acquisition Corp.
 Locust Walk Acquisition Corp. Financial ConglomeratesFinance Locust Walk Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 2, 2020 and is headquartered in Boston, MA. | Finance |
Phoenix Biotech Acquisition Corp.
 Phoenix Biotech Acquisition Corp. Financial ConglomeratesFinance Phoenix Biotech Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on June 8, 2021 and is headquartered in Oakland, CA. | Finance |
